The clinical-stage biotech is developing gene-editing CRISPR technology. Editas has reported encouraging testing results in ...

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an ...

Amid a challenging gene editing climate, partnerships between researchers, regulators, and industry remain crucial for ...

Crispr Therapeutics AG leverages CASGEVY's rollout, a robust pipeline in cardiovascular, oncology, & partnerships to large ...

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in ...

Crispr Therapeutics' current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles. Click ...

A new milestone for CRISPR: prime editing enters clinical trials, enabling precise, programmable DNA changes for treating ...